BioCentury | Jan 12, 2018
Clinical News

IDMC recommends discontinuing Phase III of Axsome's AXS-02 for complex regional pain syndrome

...Change (CGI-C) and bone turnover measured using serum carboxy terminal telopeptide of COL1 and serum procollagen type I N-propeptide (PINP)...
...bone turnover measured using serum carboxy terminal telopeptide of collagen type I (COL1) and serum procollagen type I N-propeptide (PINP)...
BioCentury | Oct 27, 2014
Clinical News

UX023: Extension study data

...1.89 mg/dL at baseline. KRN23 also increased biomarkers of bone formation and bone resorption, including procollagen type I N-propeptide (PINP)...
BioCentury | Jul 14, 2014
Clinical News

UX023: Phase I/II data

...1.89 mg/dL at baseline. KRN23 also increased biomarkers of bone formation and bone resorption, including procollagen type I N-propeptide (PINP)...
...c-terminal telopeptide of type I collage ( CTX-I ), compared to baseline. The increase in PINP...
BioCentury | Nov 5, 2012
Clinical News

Natpara: Additional Phase III data

...21 µg/L in bone alkaline phosphatase, 799 µg/L in C-terminal telopeptide (CTX), 299 µg/L in procollagen type I N-propeptide (PINP)...
BioCentury | Nov 5, 2012
Clinical News

Natpara: Phase III data

...led to increases from baseline at week 8 in bone turnover markers C-terminal telopeptide (CTX), procollagen type I N-propeptide (PINP)...
BioCentury | Feb 27, 2012
Clinical News

Implantable microchip-based drug delivery device musculoskeletal data

...said that changes in levels of serum calcium and 2 biomarkers of bone turnover - procollagen type I N-propeptide (PINP)...
BioCentury | Nov 14, 2011
Clinical News

CCX354: Phase II data

...company also said that reductions in 3 biomarkers of bone turnover - C-terminal telopeptide (CTX), procollagen type I N-propeptide (PINP)...
BioCentury | Sep 14, 2009
Clinical News

ViaDerm hPTH: Phase IIa data

...with osteoporosis showed that ViaDerm-hPTH(1-34) met the primary endpoint of an increase from baseline in PINP...
...hormone delivered using ViaDerm Micro transdermal system Indication: Treat osteoporosis Endpoint: Change from baseline in procollagen type I N-propeptide (PINP)...
BioCentury | Apr 3, 2006
Clinical News

Bonefos clodronate cancer data

...the first 5 years post-surgery. At 2 years, serum propeptides of collagen type I ( PINP...
...26% in the Bonefos group vs. a 5% increase for placebo (p<0.0001). At 1 year, PINP...
...year, Bonefos led to a significantly higher response rate, as measured by >20% decrease in PINP...
Items per page:
1 - 9 of 9